Dr. Reddy's originally launched in 1984 producing generic medications. In 1986, Reddy's started operations on branded formulations. Within a year Reddy's had launched Norilet, the company's first recognized brand in India. Soon, Reddy's obtained another success with Omez, its branded omeprazole – ulcer and reflux oesophagitis medication – launched at half the price of other brands on the Indian market at that time.Within a year, Reddy's became the first Indian company to export the active ingredients for ph
Dr. Reddy's originally launched in 1984 producing genericmedications. In 1986, Reddy's started operations on branded formulations.Within a year Reddy's had launched Norilet, the company's first recognizedbrand in India. Soon, Reddy's obtained another success with Omez, its brandedomeprazole – ulcer and reflux oesophagitis medication – launched at half theprice of other brands on the Indian market at that time.
Within a year, Reddy's became the first Indian company toexport the active ingredients for pharmaceuticals to Europe. In 1987, Reddy'sstarted to transform itself from a supplier of pharmaceutical ingredients toother manufacturers into a manufacturer of pharmaceutical products.
The company's first international move took it to Russia in1992. There, Dr. Reddy's formed a joint venture with the country's biggestpharmaceuticals producer, Biomed. They pulled out in 1995 amid accusations ofscandal, involving "a significant material loss due to the activities ofMoscow's branch of Reddy's Labs with the help of Biomed's chiefexecutive". Reddy's sold the joint venture to the Kremlin-friendlySistema group.
In 1993, Reddy's entered into a joint venture in the MiddleEast and created two formulation units there and in Russia. Reddy's exportedbulk drugs to these formulation units, which then converted them into finishedproducts. In 1994, Reddy's started targeting the US generic market by building stateof art manufacturing facility.
New drug discovery
Reddy's path into new drug discovery involved targetingspeciality generics products in western markets to create a foundation for drugdiscovery. Development of speciality generics was an important step for thecompany's growing interest in the development of new chemical entities. Theelements involved in creating a speciality generic, such as innovation in thelaboratory, developing the compound, and sending the sales team to the market,are also stages in the development of a new specialty drug. Starting withspeciality generics allowed the company to gain experience with those stepsbefore moving on to creating brand-new drugs.
Reddy's also invested heavily in building R&D labs andis the only Indian company to have significant R&D being undertakenoverseas. Dr. Reddy's Research Foundation was established in 1992 and dedicatedto research in area of new drug discovery. At first, the foundation's drugresearch strategy revolved around searching for analogues. Focus has sincechanged to innovative R&D, hiring new scientists, especially Indianstudents studying abroad on doctoral and post-doctoral courses. In 2000, theFoundation set up an American lab in Atlanta, dedicated to discovery and designof novel therapeutics. The lab is called Reddy US Therapeutics Inc (RUSTI) andits main aim is the discovery of next-generation drugs using genomics andproteomics. Reddy's research thrust focused on large niche areas in westernmarkets – anti-cancer, anti-diabetes, cardiovascular and anti-infection drugs.
Reddy's international marketing successes were built on astrong manufacturing base which itself was a result of inorganic growth throughacquisition of international and national facilities. Reddy's merged CheminorDrug Limited (CDL) with the primary aim of supplying active pharmaceuticalingredients to the technically demanding markets of North America and Europe.This merger also gave Reddy's an entry into the value-added generics businessin the regulated markets of APIs.
By 1997, Reddy's was ready for the next major step. Frombeing an API and bulk drug supplier to regulated markets like the USA and theUK, and a branded formulations supplier in unregulated markets like India and Russia,Reddy's made the transition into generics by filing an Abbreviated New DrugApplication (ANDA) in the USA. The same year, Reddy's out-licensed a moleculefor clinical trials to Novo Nordisk, a Danish pharmaceutical company.
It strengthened its Indian manufacturing operations byacquiring American Remedies Ltd. in 1999. This acquisition made Reddy’s thethird largest pharmaceutical company in India, after Ranbaxy and Glaxo (I)Ltd., with a full spectrum of pharmaceutical products, which included bulkdrugs, intermediates, finished dosages, chemical synthesis, diagnostics andbiotechnology.
Reddy’s started exploiting Para 4 filing as a strategy inbringing new drugs to the market at a faster pace. In 1999 it submitted a Para4 application for Omeprazole, the drug that had been the cornerstone of itssuccess in India. In December 2000, Reddy’s had undertaken its first commerciallaunch of a generic product in the USA., and its first product with marketexclusivity was launched there in August 2001. The same year, it also becamethe first non-Japanese pharmaceutical company from the Asia-Pacific region toobtain a New York Stock Exchange listing, ground-breaking achievements for theIndian pharmaceutical industry.
In 2001 when Reddy’s became the first Indian company tolaunch the generic drug, fluoxetine (a generic version of Eli Lilly andCompany’s Prozac) with 180 day market exclusivity in the USA. Prozac had salesin excess of $1 billion per year in the late nineties. Barr Laboratories of theU.S. obtained exclusivity for all of the approved dosage forms (10 mg, 20 mg)except one (40 mg), which was obtained by Reddy’s. Lilly had numerous otherpatents surrounding the drug compound and had already enjoyed a long period ofpatent protection. The case to allow genertic sales was heard twice by theFederal Circuit Court, and Reddy’s won both hearings. Reddy’s generated nearly$70 million in revenue during the initial six-month exclusivity period. Withsuch high returns at stake, Reddy’s was gambling on the success of thelitigation; failure to win the case could have cost them millions of dollars,depending on the length of the trial.
The fluoxetine marketing success was followed by theAmerican launch of Reddy's house-branded ibuprofen tablets in 400, 600 and 800mg sizes, in January 2003. Direct marketing under the Reddy’s brand namerepresented a significant step in the company’s efforts to build a strong andsustainable US generic business. It was the first step in building Reddy’sfully-fledged distribution network in the US market.
American IPO andexpansion into Europe
In 2001 Reddy’s completed its US initial public offering of$132.8 million, secured by American Depositary Receipts. At that time thecompany also became listed on the New York Stock Exchange. Funds raised fromthe initial public offering helped Reddy’s move into international productionand take over technology-based companies.
In 2002, Reddy’s started its European operations byacquiring two pharmaceutical firms in the United Kingdom. The acquisition ofBMS Laboratories and its wholly owned subsidiary, Meridian UK, allowed Reddy’sto expand geographically into the European market. In 2003 Reddy’s alsoinvested $5.25 million (USD) in equity capital into Bio Sciences Ltd.
Auriegene Discovery Technologies, a contract researchcompany, was established as a fully owned subsidiary of Reddy’s in 2002.Auriegene's objective was to gain experience in drug discovery through contractresearch for other pharmaceutical companies. Reddy’s entered into a ventureinvestment agreement with ICICI Bank, an established Indian banking company.Under the terms of the agreement, ICICI Venture agreed to fund the development,registration and legal costs related to the commercialization of ANDAs on apre-determined basis. Upon commercialization of these products, Dr. Reddy'spays ICICI Venture royalty on net sales for a period of 5 years.
By the early 2000s, Reddy's had successfully grown into afully integrated pharmaceutical company. It had been less than a decade sincethe beginning of its expansion in the mid-nineties. The company's growth so farhad been founded on a targeted program of inorganic growth and investments inprocess R&D. It had chosen a "high risk-high gain" strategy forgrowth by going into direct competition with existing patent holders. A majorchallenge for Reddy’s in the early 2000s was to find ways to de-risk itsoverall strategy. The company elected to expand globally, and went on a spreeof acquisitions.
In March 2002, Dr. Reddy’s acquired BMS Laboratories,Beverley, and its wholly owned subsidiary Meridian Healthcare, for 14.81million Euros. These companies deal in oral solids, liquids and packaging, withmanufacturing facilities in London and Beverley in the UK. Recently, Dr.Reddy’s entered into an R&D and commercialization agreement with ArgentaDiscovery Ltd., a private drug development company based in the UK, for thetreatment of COPD.
With growing success in the generics market, Reddy’s alsocame to realize the need for developing marketing and distribution capabilitiesin the USA. Reddy’s was considering several options in 2003 for marketing theirhypertension product. The company already had one tie-up with PharmaceuticalResources, Inc. to market Fluoxentine 40 mg tablets. It also had a tie-up withPar Pharmaceuticals Inc., to produce and market over-the-counter drugs in theU.S. In addition to the United States, Reddy’s generics business hadestablished a presence in the UK, which became a platform for expansion into othercountries in Europe. Its API business had sales in over 60 countries, with theUS and India being the most significant revenue contributors. The brandedformulations business was active in over 30 countries and Reddy’s was asignificant player in the Indian and Russian markets. The business planned tosignificantly increase its presence in China, Brazil and Mexico in the nearfuture.
Dr. Reddy’s entered into a 10-year agreement withRheoscience A/S of Denmark for the joint development and commercialization ofBalaglitazone (DRF-2593), a molecule for the treatment of type-2 diabetes.Rheoscience holds this product’s marketing rights for the European Union andChina, while the rights for the US and the rest of the world will be held byDr. Reddy’s. Dr. Reddy’s conducted clinical trials of its cardiovascular drugRUS 3108 in Belfast, Northern Ireland, in 2005. The trials were conducted tostudy the safety and the pharmacokinetic profiles of the drug, which isintended for the treatment of atherosclerosis, a major cause of cardiovasculardisorders.
Dr. Reddy’s entered into a marketing agreement with EurodrugLaboratories, a pharmaceutical company based in Netherlands, for improving itsproduct portfolio for respiratory diseases. It introduced a second-generationxanthine bronchodilator, Doxofylline, which is used for the treatment of asthmaand chronic obstructive pulmonary disease (COPD) patients.
In 2004, Reddy’s acquired Trigenesis Therapeutics Inc; aUS-based private dermatology company. This acquisition gave Reddy’s access toproprietary products and technologies in the dermatology sector.
Dr. Reddy’s Para 4 application strategy for generic businessreceived a severe setback when Reddy’s lost the patent challenge in the case ofPfizer’s drug Norvasc (amlodipine maleate), a drug indicated for the treatmentof hypertension and angina. The cost involved in patent litigation as well asthe unexpected loss of the patent challenge affected Reddy’s plans to startspeciality business in the US generic markets.
In March 2006, Dr. Reddy’s acquired Betapharm ArzneimittelGmbH from 3i for 480 million Euros. This is one of the largest-ever foreignacquisitions by an Indian pharmaceutical company. Betapharm is Germany’sfourth-largest generics pharmaceuticals, with a 3.5% market share, including150 active pharmaceutical ingredients.
Reddy’s has promoted India’s first integrated drugdevelopment company Perlecan Pharma Pvt Ltd together with ICICI venturescapital fund management company Ltd and Citigroup Venture Capital Internationalgrowth partnership Mauritius Ltd. The combined entity will undertake clinicaldevelopment and out-licensing of new chemical entity assets.
Dr. Reddy's is presently licensed by Merck & Co. to sellan authorized generic version of the popular drug simvastatin (Zocor) in theUSA. Since Dr. Reddy's has a license from Merck, it was not subject to theexclusivity period on generic simvastatin.
As of 2006, Dr. Reddy’s Labs crossed $500 million USD inrevenues, flowing from their APIs, branded formulations and generics segments;the former two segments account for almost 75% of revenues. Dr. Reddy's dealsin and manages all the processes, from the development of the API to thesubmission of finished dosage dossiers to the regulatory agencies.
Issues and recalls
In September 2005, Dr. Reddy's spun off its drug discoveryand research wing into a separate company called Perlecan Pharma PrivateLimited. At the time, this was hailed as an innovative move, but in 2008, thecompany it had to be wound down due to funding constraints. Dr. Reddy's wasthe first Indian pharma company to attempt such an effort to de-couple risk ofdrug discovery from the parent company by creating a separate company withexternal source of funding. Perlecan Pharma was partially funded by ICICIVenture Capital and Citigroup Venture International, both of which held a 43%stake in Perlecan for an estimated $22.5 million. However, the company wasforced to buy back the Perlecan shares from ICICI and Citigroup due to doubtsregarding the commercial viability of the drug candidates that were inPerlecan's pipeline. At that point, Perlecan became a wholly owned subsidiary.In the board meeting of October 23, 2008, the company chose toamalgamate/absorb Perlecan, thereby making it an in-house research facility, asit was before 2005.
In 2009, the company did a U-turn and has handed overdiscovery research and related intellectual property to its Bangalore-basedsubsidiary, with the possibility of spinning it off as a different entityaltogether. "The company may be hoping to find a strategic partner in thefuture to share the risks and research funding."
Established in 1984, Dr. Reddy's Laboratories Ltd. (NYSE:RDY) is an integrated global pharmaceutical company, committed to providingaffordable and innovative medicines for healthier lives. Through its threebusinesses - Pharmaceutical Services and Active Ingredients, Global Genericsand Proprietary Products – Dr. Reddy’s offers a portfolio of products andservices including Active Pharmaceutical Ingredients (APIs), CustomPharmaceutical Services (CPS), generics, biosimilars, differentiatedformulations and News Chemical Entities (NCEs).
Pharmaceutical Services & Active Ingredients (PSAI)
Humanity’s health needs are greater than any one company’sability to solve them; yet we can work with others to bring new drugs quicklyto the market and provide the building blocks of affordable medicines. Throughour PSAI business, which comprises the Active Pharmaceutical Ingredients (API)and Custom Pharmaceutical Services (CPS) businesses, we offer IP advantaged,speedy product development and cost-effective manufacturing services to ourcustomers – generic companies and innovators. This allows us to help make goodmedicines available to more people around the world. The core strengths of ourPSAI business are the state-of-the-art infrastructure, resources and skills weare able to offer to our customers:
- Large and diverse product portfolio
- Eight FDA-inspected plants and three technology centers
- World class chemistry expertise
- Robust, large-scale manufacturing capabilities
- Intellectual Property (IP) driven product development for freedom to operate
- Total, seamless supply chain management
Both in the developing and developed world, it is a grimfact that millions of people suffer from treatable illnesses and disease simplybecause they cannot afford the medicines that will restore them to health. Evenin high income countries like the US, brand name drugs are often prohibitivelyexpensive, particularly for the growing numbers of uninsured. Around the world,having access to lower-cost generic medicines can mean the difference betweenhealth and sickness, solvency and bankruptcy for countless people.
Generic drugs hold great promise for the future. Growing acceptance of genericsand favorable legislation in many geographies, combined with the large volumeof branded products losing patent protection over the coming years is expandingthe generic pharmaceuticals market.
Through our branded and unbranded Global Generics business, we fulfill ourpurpose of providing affordable medicines to more people around the world byoffering lower-cost alternatives to highly-priced innovator brands bothdirectly and through key partnerships.
Our capabilities span the entire value chain – from process development of theactive pharmaceutical ingredient (API) to submission of the finished dosagedossier to the regulatory agencies – giving us control over the supply chainand the ability to offer high quality products at the right time and atcompetitive prices. Our state-of-the-art manufacturing facilities are ISO14001and ISO9001 certified and have an excellent record of regulatory compliance.Our generics business is supported by our integrated Product DevelopmentInfrastructure which is dedicated to bringing new medicines to the market.
Today, we have a strong presence both in highly regulated markets like the US,UK and Germany and in emerging markets, including India, Russia, Venezuela,Romania, and CIS (Belarus, Ukraine and Kazakhstan). Moreover, we are steadilybuilding our presence in other key markets.
Science and innovation hold the key to unlocking themysteries of diseases that continue to afflict humanity. While scientificadvances have either obliterated many deadly diseases or brought them undercontrol, there are still far too many diseases that lack satisfactory treatmentsor cures. These unmet medical needs of humanity drive our research enterprise.
Our Proprietary Products business comprises NCE research, Biologics andDifferentiated Formulations. In each of these areas, we are building world-class capabilities and partnershipsto accelerate the discovery and development of new and improved therapies.
Within our highly advanced and integrated R&D infrastructure, scientistswith diverse functional expertise seek innovative solutions to medical needs inthe therapeutic areas of metabolic diseases, anti-infectives and inflammatorydisease. Our scientific capabilities spana wide range of areas, such as medicinal chemistry, analytical chemistry,pharmacology, genomics, proteomics, molecular biology, microbiology, toxicology,formulation and clinical development.
Board of Directors
Dr. Reddy’s Board of Directors comprises eminent individuals from diversefields. The Board acts with autonomy and independence in exercising strategicsupervision, discharging its fiduciary responsibilities, and in ensuring thatthe management observes the highest standards of ethics, transparency anddisclosure.
Our directors are experts in the diverse fields of medicine, chemistry andmedical research human resource development, business strategy, finance, andeconomics. They review all significant business decisions, including strategicand regulatory matters. Every member of the Board, including the non-executivedirectors, has full access to any information related to our company.
Committees appointed by the Board focus on specific areas, take decisionswithin the authority delegated to them and make specific recommendations to theBoard on matters in their areas or purview.
Alliancing & Partnership
Our Partnering Philosophy
At the core of each successful partnership is a great relationship based ontrust and mutual respect. As we work towards fulfilling our core purpose weshare your aspirations. We recognize and embrace the fact that our partners area core component of this strategy.
We understand that partnerships are successful when benefits accrue to bothparties. They are built on a shared vision with well-defined and agreed-upongoals. We also know that that the partners’ thinking and interests may notalways be identical, but that we share the same goal—a successful product.
Our shared partnership successes are at the very heart of our business. Fromour first meeting through product launch and beyond, we stand behind our beliefin true partnership thereby combining our strengths and sharing our successes.Dr. Reddy's firmly believes that the right alliances can contributesignificantly to the success of our partners as well as to our own strategy andsustainable growth.
Transparent and Simple process:
Clarity of thought, Speed of execution, Flexibility, creativity, andtransparency are critical components of our negotiation and transactionprocess. As no two deals are the same, we work with potential partners tostructure deals through customized approaches that allow both partners toleverage unique capabilities and assets in order to achieve common goals.
A simple and streamlined process to progress our partnering discussions anda flat organizational structure facilitates rapid decision making from initialscreening to execution.
As a company that evaluates 100+ business development opportunities in anygiven year (many of which come to closure), we value the time and resources ourpotential partners commit to explore and complete any potential partnership.Dr. Reddy’s emphasizes a transparent and collaborative negotiation process andprompt decision making.
We bring a reputation for acting swiftly and being flexible. We will workwith you to reach an agreement with which you will be comfortable and that willhead us in the right direction toward shared success.
Sustained relationship based on trust and mutual respect:
Our robust alliance management principles and practices allow successfulexecution of joint initiatives.
Dr. Reddy’s is committed to ensuring that our partnerships succeed andflourish.
At Dr. Reddy’s, sustainability is a multi-dimensional aspiration, which hasits roots in the very purpose of our existence – providing affordable medicinesto people around the world and meeting unmet medical needs through innovation.Our business, by its very nature, serves a social good, so we have a far deeperreason than profits alone to drive our performance.
For us, building a sustainable organization is not a trend we blindlyfollow; it is intrinsic to how we have operated for decades. To us, acommitment to sustainability means a commitment to fulfilling our obligationsto all of our stakeholders -- our customers & partners, employees,shareholders and society. Thus, while optimizing profitability may be one measurementof our performance, we also judge our success by our performance with regard tothe communities in which we live and work, the environment and our employees.We understand that it is only by increasing value to all of these stakeholdersthat we can build an ever flourishing and lasting organization.
While sustainability thinking was always woven into the fabric of ourorganization, we formally declared our intent to institutionalize it in 2004,when we first began to publicly report on our sustainability practices. We annually publish our Sustainability Report with direction from theguidelines recommended by Global Report Initiative G3, covering social,ethical, economic, safety and environmental aspects of our business.
Pharma Services &Active Ingredients
- Six FDA-approved plants in India
- One FDA-approved plant in Mexico
- One FDA-approved plant in Mirfield, UK
- Three Technology development centers
(Two in Hyderabad, India; One in Cambridge, UK)
· Integrated Product development Capabilities that includes APIdevelopment, Formulations development and analytical development skills.
· One IntegratedProduct development facility in Hyderbad, India.
- Seven Formulation plants in India (Two USFDA inspected)
- Two USFDA inspected plant in USA
New Chemical Entities
Research in the areas of metabolic, cardiovascular,anti-bacterials, and pain & inflammation.
- Biologics development center
- GMP production
- E coli and mammalian cell platforms
Dr.Reddy's Laboratories Limited
Door No 8-2-337,
Road No 3, Banjara Hills,
Hyderabad - 500034.
ImportantNote: Please visit the Careers section to apply for a job. For any recruitmentrelated queries please contact: firstname.lastname@example.org. Resume sent to any of the emailIDs will not be considered.
Dr. Reddy's Laboratories Ltd.
8-2-337, Road No 3,
Banjara Hills, Hyderabad - 500034,
Andhra Pradesh - INDIA
Tel: +91 40 49002900
Fax: +91 40 49002999
Dr. Reddy's Laboratories Ltd.
Bollaram Road, Miyapur,
Hyderabad, Andhra Pradesh,
Dr. Reddy's Laboratories Ltd.
Hyderabad 500 016, INDIA
Dr. Reddy's Laboratories Ltd.
Hyderabad 500 016, INDIA
Finished Dosage –Generics
Dr. Reddy's Laboratories Inc.
200 Somerset Corp. Blvd.
Bridgewater, NJ 08807
Dr. Reddy's Foundation
Tel: +91-40-65343424, 23304199 / 1868
Why Dr. Reddy’s?
Why should you join Dr. Reddy’s?
Established in 1984, Dr. Reddy’s Laboratories (NYSE: RDY) isan emerging global pharmaceutical company.
As a fully integrated pharmaceutical company, our purpose is to provideaffordable and innovative medicines through our three core businesses:
- Because this is a company with a fast-growing global presence.
Because it has chosen to make affordable medicines and reach them across the world, especially to the unreached.
Because here, merit and initiative take you places; to new positions, new domains, new responsibilities and new countries.
Because not just us but the world thinks we are one of the best places to grow a career in.
We owe this recognition to the constantly evolving team andorganisational development efforts led by teams at all levels. And apart fromconstantly studying and adapting best practices from across the globe, we haveno-holds barred, organisation-wide surveys of all stakeholders understand fromthem what needs to improve. This preoccupation to make Dr. Reddy’s aprogressive work place shows in our transparent recruitments, growth opportunities,best in class team welfare and well-being enablers and in the emergence of Dr.Reddy’s as one of the most HR positive companies in the sector.
Why I Enjoy Being at Dr. Reddy’s?
"It'sinclusive: I am visually challenged and this means there are things that I canand cannot do. The company has provided me with a lot of technical tools thatmake it possible for me to do writing based on audio inputs and outputs."
"Dr.Reddy's has offered me a dynamic growth path over the last 13 years .It is wellpoised to grow exponentially & I would like to be a part of the growthstory."
The company is quick to appreciate initiative and alsosupports it with action. It hones your skills and broadens your knowledge byhuge leaps within a very short period of time. Moreover, the independence givento you by your seniors to operate is hugely valued and inspires you to come upwith novel ideas.
Life @ Dr. Reddy’s
Join Dr. Reddy’s
There are several options through which we can worktogether.
If you are studying: "You need the right transitionplatform from university study to the real business world. By working on 'liveprojects' with various functions, you get to learn the intricacies of corporatefunctions through on-the-job experience, which will help you appreciatedepartmental compliments later in your careers.
You also stand a chance to win Pre-Placement Offers (PPO).The top performers among the interns make it into the company as employees onits rolls. Being selected as an intern is half the battle won.
Nearly 40% of our interns end up as regular members of theDr. Reddy's team.
Campus recruitments: "We recruit bright and eager mindsfrom premier Business and Technical schools. We look for those who dare todream. Love ambiguity and challenge. Are tickled by the thought of growingacross experience. A written evaluation followed by a group discussion and apersonal interview is the norm for short-listing potential candidates."
Current Openings: Click here to know the current openingsthat we are recruiting for and send your CV directly from this link to ourTalent Acquisition Team.
Express an Interest: If you are keen to work with us, eventhough you cannot find a suitable position to apply through the website. Writeto us why you want to join us and what you have done exceptionally well in thepast. And along with this covering note mail your CV to our Talent AcquisitionTeam, with the following subject line: Keen to work with you: I’m goodat...(fill in your key strength here).
Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3
Banjara Hills, Hyderabad
Hyderabad - 500 034
Dr. Reddy's Laboratories Ltd.
Block 3, 5 Floor,
HYDERABAD 500 016 India
Tel: 040-5502 2500
Products of Dr. Reddy's
|ACETEC ||GLIMY-MP2 ||RELENT TAB |
|AFFEN PLUS ||GLIMY-P ||RELENT-L |
|ALADIN ||GLIOZ ||RESILO |
|ALFOO ||GRAFEEL ||RESILO-H |
|ANAIDA ||GRAFEEL PFS ||RESWAS |
|ANTOXID ||GRASTIM ||RETOZ |
|ANTOXID-HC ||GRIS-OD ||REVIBRA |
|ATOCOR ||HILIN ||REZUM |
|ATOCOR-E ||HYDROHEAL-AM ||RIFLUX FORTE |
|ATOCOR-F ||IBUCLIN ||RIFLUX FORTE TAB |
|BAPTER ||IBUCLIN JR ||RIFLUX |
|BECELAC ||IMNIT ||RIFLUX TAB |
|BECELAC FORTE ||IRNOCAM ||ROSUVASTAT |
|BECELAC-PB ||K-CIT ||ROZAT |
|BECOZINC ||K-CIT TAB ||ROZAT-F |
|BECOZINC SYR ||KETOROL ||RUFFY |
|BETAONE-XL ||KETROL ||RUPANEX |
|BIO-E CAPS ||LACTIFLORA ||RUPANEX-M |
|BISPEC ||LANZAP ||SALICYLIX-SF |
|BLAZTERE INJ ||LENANGIO ||SALMETER |
|CANTAR ||LEON ||SAL-MUCOLITE |
|CANTOP ||LEON-OZ ||SENQUEL |
|CAPIIBINE ||LOMADAY ||SENQUEL-AD |
|CARDIOPRIL ||LOMTIN ||SENQUEL-F |
|CARDIOPRIL-H ||LOSTATIN ||S-FLO |
|CEFALONG-DS ||MEGA-3 ||SPARACID |
|CELADRIN ||METORAL ||SPARACID-DS |
|CETRINE ||METROHEX ||SPARFLO |
|CHEERIO ||MET-STAMLO ||SPONTREL |
|CIPROLET ||MINTOP FORTE ||STAMACE |
|CIPROLET DPS ||MINTOP ||STAMLO BETA |
|CIPROLET-A ||MITOTAX ||STAMLO BETA-M |
|CIPROLET-AH ||MOREASE ||STAMLO |
|CIPROLET-IV ||MOREASE-I ||STAMLO-D |
|CLAMP ||MUCOLITE ||STOLIN |
|CLAMP KID ||MUCOLITE SYR ||STOLIN TOOTHPASTE |
|CLAMP KID FORTE ||MUCOLITE-SR ||STOLIN-R |
|CLEARZ ||MYEZOM ||STYPTOCHROME INJ |
|CLEARZ PLUS ||NATCAL ||STYPTOMET |
|CLOHEX 150 ||NATCAL SUSP ||STYPTOVIT-K |
|CLOHEX PLUS ||NATCAL-1000 ||SUEZ |
|COMBIHALE-FB ||NATCAL-D3 ||SUPAMOVE |
|COMBIHALE-FB INHALER ||NEXRET ||SUPANAC |
|COMBIHALE-FF ||NIALIP ||TAZZLE |
|COMBIHALE-FT ||NIAP ||TEFIFIN |
|CRESP ||NILTAN ||TELSARTAN-AM |
|CRESP INJ ||NILWART ||TELSARTAN-ATR |
|CRESP-PFS ||NISE GEL ||TELSARTAN-H |
|CYTOGEM ||NISE ||TENFLAY |
|DACOTIN ||NISE-MD ||THAANGIO |
|DENFOS ||NISE-MR ||TORQ SR |
|DEVIPROST ||N-MET G ||TORQ |
|DIALEX ||N-MET ||TRICHODOL |
|DIALEX-DC ||NORILET DPS ||TROSPA |
|DIALEX-PC ||NORILET ||TWINKIT |
|DIAVISTA ||NORILET-A ||ULTRAVEX |
|DIAVISTA-M ||NORILET-D ||ULTRAVEX-S6 |
|DICYNENE ||NOVIGAN-M ||VEGAZ-OD |
|DINORIPE ||OMEZ INSTA SACHET ||VELOCIT |
|DOCETERE ||OMEZ MUPS ||VENUSIA |
|DOLOGEL ||OMEZ ||VIBOLIV |
|DOLOGEL-CT ||OMEZ-D ||VOZUCA-M |
|DOXIUM ||OMEZ-FF ||WHITFIELD-SF |
|DOXOBID ||OPTISULIN ||XELENA |
|DOXT ||ORETA ||Z & D |
|DOXT-S ||OSETRON ||ZENAX |
|DRAB ||OVISTA ||ZEXTRA |
|DUTALFA ||OXIT ||ZORAN |
|DUTAS ||OXIT-OZ ||ZOVANTA KIT |
|DUTAS-T ||PALZEN ||ZOVANTA |
|DYNAPRES ||PECEF ||ZOVANTA-D |
|EBERNET ||PEDICLORYL ||ZUVAIR |
|EBIZA-L ||PEG-GRAFEEL || |
|ECONORM CAP ||PEMGEM || |
|ECONORM ||PERTI || |
|EDETO ||PG TAB || |
|ELINA ||PLAGRIL GOLD || |
|EMLUCAST ||PLAGRIL || |
|EMPOV ||PLAGRIL-A || |
|ENAM ||PLERMIN || |
|ENAM-D ||PRAVY-ST || |
|ETURA ||RAFREE || |
|EXECARE ||RAZO || |
|EXIFINE CRM ||RAZO-D || |
|EXIFINE ||REBALANZ || |
|FINARA ||RECLIDE || |
|FINAST ||RECLIMET || |
|FINAST-T ||REDEFINE || |
|FINAX ||REDICATE || |
|FINRID ||REDICATE-CLAV || |
|FIONA ||REDIGREL || |
|FITTYDENT DENTURE ADHESIVE ||REDIHEALTH || |
|FITTYDENT DENTURE CLEANSER ||REDIHEALTH SYR || |
|FOSEND ||REDIHOPE || |
|GLA-120 ||REDIOUT || |
|GLA-M ||REDIPIL || |
|GLIMY ||REDISPAR || |
|GLIMY-M FORTE ||REDITUX || |
|GLIMY-M ||REDOTIL || |
|GLIMY-MP1 ||RELENT || |